Advertisement

Erkrankungen von Herz und Gefäßen

  • Helmut Drexler
  • Karl-Heinz Kuck
  • Sabine Ernst
  • Hans-Peter Hermann
  • Gerd Hasenfuss
  • Dieter Horstkotte
  • Cornelia Piper
  • Juliane Wagener
  • Bodo-Eckhard Strauer
  • Heinz-Peter Schultheiss
  • Uwe Kühl
  • Michael Brehm
  • Dirk Hausmann
  • Franz-Josef Neumann
  • Albert Schömig
  • Christian Hamm
  • Danilo Fliser
  • Jan Menne
  • Jörg Radermacher
  • Hermann Haller
  • Christoph A. Nienaber
  • Curt Diehm
  • Gerd Hausdorf
  • Dirk Hausmann
  • Bodo Eckhard Strauer
  • Andreas Schwalen
  • Heinz-Peter Schultheiss
  • Uwe Kühl

Zusammenfassung

Einleitung. Bradykarde Rhythmusstörungen entstehen infolge einer Verzögerung oder eines Ausfalls der Erregungsentstehung und der Erregungsleitung. Therapeutische Konsequenzen ergeben sich nur, wenn in Folge der Rhythmusstörung Symptome auftreten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American College of Cardiology/American Heart Association task force on practice guidelines (2001) ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. JACC 38: 2101–2113CrossRefGoogle Scholar
  2. CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 316: 1429–1435CrossRefGoogle Scholar
  3. Digitalis Investigative Group (1997) The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–33CrossRefGoogle Scholar
  4. Kass DA, Chen CH, Curry C, Talbot M, Berger R, Fetics B, Nevo E (1999) Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 99: 1567–1573PubMedCrossRefGoogle Scholar
  5. Leitlinien zur Therapie der Herzinsuffizienz der Deutschen Ge- sellschaft für Kardiologie (1998) Z Kardiol 87: 645–661Google Scholar
  6. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001–2007CrossRefGoogle Scholar
  7. Packer M, Bristow MR, Cohn JN, Colucci WS et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349–1355PubMedCrossRefGoogle Scholar
  8. Packer M, Coats AJ, Fowler MB et al. (Carvedilol Prospective Randomized Cumulative Survival Study Group) (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658Google Scholar
  9. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717PubMedCrossRefGoogle Scholar
  10. Remme WJ, Swedberg K (Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology) (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527–1560CrossRefGoogle Scholar
  11. SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 327: 685–691CrossRefGoogle Scholar
  12. Braunwald E, Zipes DP, Libby P (2001) Heart disease, a Textbook of cardiovascular medicine, 6th edn. W.B. Saunders, PhiladelphiaGoogle Scholar
  13. Carabello BA, Crawford FA (1997) Valvular heart disease. New Engl J Med 337: 32–41PubMedCrossRefGoogle Scholar
  14. Executive Summary Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (1998) Guidelines for the management of patients with valvular heart disease. Circulation 98: 1949–1984CrossRefGoogle Scholar
  15. Gruneberg RN, Wilson APR (1996) Dosage recommendations for teicoplanin: what have we learned?. Chemother J 11 (Suppl 5): 13–15Google Scholar
  16. Gutschik E (1999) New developments in the treatment of infective endocarditis (infective cardiovasculitis). Int J Antimicrob Agents 13 (2): 79–92PubMedCrossRefGoogle Scholar
  17. Horstkotte D (1995) Mikrobiell verursachte Endokarditis. Steinkopff, DarmstadtCrossRefGoogle Scholar
  18. Horstkotte D, on behalf of the The Task Force on Infective Endocarditis of the European Society of Cardiology (2002) Recommendations for prevention, diagnosis and treatment of infective endocarditis. Eur Heart J (in press)Google Scholar
  19. Horstkotte D, Piper C, Niehues R (1994) Prognose und Nachsorge mikrobiell verursachter Endokarditiden. In: Gahl K (Hrsg) Infektiöse Endokarditis. Steinkopff, Darmstadt, S 325–358Google Scholar
  20. Horstkotte D (2000) Endocarditis: epidemiology, diagnosis and treatment. Z Kardiol 89 (Suppl 4): IV2–11Google Scholar
  21. Meyer T, Reiter H, Mirzaie M, Hasenfuß G, Unterberg C (2000) Symptomatik der primären Endokardfibroelastose im Erwachsenenalter. Dtsch Med Wochenschr 125: 168–171Google Scholar
  22. Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74: 275–284PubMedCrossRefGoogle Scholar
  23. Murphy PT, Fenelly DF, Stuart M, O’Donnell JR (1990) Alpha-interferon in a case of hypereosinophilic syndrome. Br J Haematol 75: 619–620PubMedCrossRefGoogle Scholar
  24. Mylonakis E, Calderwood SB (2001) Infective endocarditis in adults. N Engl J Med. 345 (18): 1318–1330CrossRefGoogle Scholar
  25. Piper C, Hetzer R, Körfer R, Bergemann R, Horstkotte D (2002) The importance of secondary mitral valve involvement in primary aortic valve endocarditis: the kissing vegetation. Eur Heart J 23: 79–86PubMedCrossRefGoogle Scholar
  26. Piper C, Wiemer M, Schulte HD, Horstkotte D (2001) Stroke is not a contraindication for urgent valve replacement in acute infective endocarditis. J Heart Valve Dis 10: 703–711PubMedGoogle Scholar
  27. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H (2000) Predictors of outcome in severe, asymptomatic aortic stenosis. New Engl J Med 343: 611–617PubMedCrossRefGoogle Scholar
  28. Thomas L, Horstkotte D, Rosin H (1986) Imipenem/Cilastatin bei penci1lina11ergischen Patienten mit Enterokokken-Endokarditis. FAC 5: 389–393Google Scholar
  29. Richardson P, McKenna W, Bristow M et al. (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies [news]. Circulation 93: 841–842PubMedCrossRefGoogle Scholar
  30. Elliot P (2000) Diagnosis and management of dilated cardiomyopathy. Europ Heart J 84: 106–112CrossRefGoogle Scholar
  31. Schultheiss HP, Pauschinger M, Dörner A, Kühl U, Bilger J, Schwimmbeck PL (1998) Entzündliche Herzmuskelerkrankungen. In: Ganten D, Ruckpaul K (Hrsg) Handbuch der molekularen Medizin, Band: Herz-Kreislauf-Erkrankungen. Springer, Berlin Heidelberg New York Tokyo, S 111–146CrossRefGoogle Scholar
  32. Hoppe UC, Erdmann E (1998) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 87: 645–661PubMedGoogle Scholar
  33. Massie BM, Fisher SG, Radford M et al. (1996) Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 93: 2128–2134Google Scholar
  34. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Cu-riel R (1994) Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344: 493–498 (see comments)Google Scholar
  35. Deswal A, Bozkurt B, Seta Y et al. (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99: 3224–3226 (see comments)Google Scholar
  36. Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. New Engl J Med 336: 775–785PubMedCrossRefGoogle Scholar
  37. Pollick C (1982) Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramid. N Engl J Med 307: 997–999PubMedCrossRefGoogle Scholar
  38. Schulte HD, Bircks W, Losse B (1987) Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy ( HOCM ). Z Kardiol 76: 145–151Google Scholar
  39. ACE Inhibitor Myocardial Infarction Collaborative Group (1998) Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97: 2202–2212CrossRefGoogle Scholar
  40. AIRE investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828Google Scholar
  41. Arntz HR, Tebbe U, Schuster HP, Sauer G, Meyer J (2000) Leitlinien zur Diagnostik and Therapie des akuten Herzinfarktes in der Prähospitalphase. Z Kardiol 89: 364–372CrossRefGoogle Scholar
  42. Braunwald E, Zipes DP, Libby P (2001) Acute myocardial infarction. In: Heart disease: A textbook of cardiovascular medicine, 6th ed. WB Saunders, Philadelphia, p 1114–1219Google Scholar
  43. Brener SJ, Barr LA, Burchenal JE et al. (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98: 734–741PubMedCrossRefGoogle Scholar
  44. Grines CL, Cox DA, Stone GW et al. (1999) Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 341: 1949–1956PubMedCrossRefGoogle Scholar
  45. GUSTO investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682CrossRefGoogle Scholar
  46. Montalescot G, Barragan P, Wittenberg O, Ecolan P et al. (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. New Engl J Med 344: 1895–1903PubMedCrossRefGoogle Scholar
  47. Neumann FJ, Kastrati A, Schmitt C et al. (2000) Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35: 915–921PubMedCrossRefGoogle Scholar
  48. Pfeffer MA, Braunwald E, Moye LA et al. (SAVE Investigators) (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327: 669–677Google Scholar
  49. Ryan TJ, Antman EM, Brooks NH et al. (1999) ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. Circulation 100: 1016–1030Google Scholar
  50. Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009PubMedCrossRefGoogle Scholar
  51. Schömig A, Kastrati A, Dirschinger J et al. (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 343: 385–391PubMedCrossRefGoogle Scholar
  52. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P (1999) Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353: 1547–1557Google Scholar
  53. Zijlstra F, Hoorntje JC, de Boer MJ et al. (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341: 1413–1419PubMedCrossRefGoogle Scholar
  54. Cigarroa JE, Isselbacher EM, DeSanctis RW, Eagle KA (1993) Diagnostic imaging in the evaluation of suspected aortic dissection: old standards and new directions. N Engl J Med 328: 35–43PubMedCrossRefGoogle Scholar
  55. Hagan PG, Nienaber CA, Isselbacher EM et al. (2000) The international registry of acute aortic dissection (IRAD). New insights into an old disease. JAMA 283: 897–903Google Scholar
  56. Hirst A, Johns VJ, Cline SJ (1958) Dissecting aneurysm of tha aorta: a review of 505 cases. Medicine 37: 217–279PubMedCrossRefGoogle Scholar
  57. von Kodolitsch Y, Krause N, Spielmann R, Nienaber CA (1999) Diagnostic potential of combined transthoracic echocardiography and X-ray computed tomography in suspected aortic dissection. Clin Cardiol 22: 345–452PubMedCrossRefGoogle Scholar
  58. Kouchoukos NT, Dougenis D (1997) Surgery of the thoracic aorta. N Engl J Med 336: 1876–1888PubMedCrossRefGoogle Scholar
  59. Nienaber CA, Fattori R, Lund G et al. (1999) Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. N Engl J Med 340: 1539–1545PubMedCrossRefGoogle Scholar
  60. Nienaber CA, Spielmann RP, von Kodolitsch Yet al. (1992) Diagnosis of thoracic aortic dissection: magnetic resonance imaging versus transesophageal echocardiography. Circulation 85: 434–447PubMedCrossRefGoogle Scholar
  61. Nienaber CA, von Kodolitsch Y, Nicolas Vet al. (1993) The diagnosis of thoracic aortic dissection by noninvasive imaging procedures. N Engl J Med 328: 1–9PubMedCrossRefGoogle Scholar
  62. Nienaber CA, von Kodolitsch Y, Petersen B et al. (1995) Intramural hemorrhage of the thoracic aorta: diagnostic and therapeutic implications. Circulation 92: 1465–1472PubMedCrossRefGoogle Scholar
  63. Nienaber CA, von Kodolitsch Y (1999) Therapeutic management of patients with Marfan Syndrome. Cardiol Rev 7: 332–341PubMedCrossRefGoogle Scholar
  64. Nienaber CA, von Kodolitsch Y (1998) Diseases of the aorta. In: Reichek N (ed) Cardiology clinics, Vol 16, 2. WB Saunders, Philadelphia, p 295–314Google Scholar
  65. Barst RJ, Rubin LJ, Long WA et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296–302Google Scholar
  66. Channick RN, Simonneau G, Sitbon 0 (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119–1123Google Scholar
  67. Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J (1997) Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 52: 674–679PubMedCrossRefGoogle Scholar
  68. Haverich A, Wiebe K (1999) Chronische pulmonale Hypertension: Chirurgische Therapie. Internist 40: 764–771Google Scholar
  69. Hoeper MM, Schwarze M, Ehlerding S et al. (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866–1870PubMedCrossRefGoogle Scholar
  70. Köhler D, Criee CP, Raschke F (1997) Leitlinien zur häuslichen Sauerstoff- und Heimbeatmungstherapie. Med Klinik 92: 2–6CrossRefGoogle Scholar
  71. Köhler D, Schönhofer B (1999) Sauerstofflangzeittherapie und Heimbeatmung bei chronischem Cor pulmonale. Internist 40: 756–763PubMedCrossRefGoogle Scholar
  72. McLaughlin VV, Genthner DE, Panetta MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273–277PubMedCrossRefGoogle Scholar
  73. Orth M, Rasche K, Schultze-Werninghaus G (1999) Chronisches Cor pulmonale: Epidemiologie, Pathophysiologie und Klinik. Internist 40: 722–728Google Scholar
  74. Rich S, Kaufmann E, Levi PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81PubMedCrossRefGoogle Scholar
  75. Steiner S, Perings C (1999) Pulmonalarterielle Hypertonie und Cor pulmonale bei obstruktiver Schlafapnoe. Internist 40: 739–746PubMedCrossRefGoogle Scholar
  76. Strauer BE (1991) Cor pulmonale. In: Riecker G, Erdmann E (Hrsg) Klinische Kardiologie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  77. Aretz HT (1987) Myocarditis: the Dallas criteria. Hum Pathol 18: 619–624PubMedCrossRefGoogle Scholar
  78. Badorff C, Berkely N, Mehrotra S, Talhouk JW, Rhoads RE, Knowlton KU (2000) Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem 275: 11191–11197PubMedCrossRefGoogle Scholar
  79. Bardorff C, Kühl U, Noutsias M, Schultheiß HP (1997) Cell-mediated cytotoxicity in idiopathic dilated cardiomyopathy. Correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 29: 429–434Google Scholar
  80. Bowles NE, Richardson PJ, Olsen EG, Archard LC (1986) Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1: 1120–1123PubMedCrossRefGoogle Scholar
  81. Doerner A, Pauschinger M, Schwimmbeck PL, Kuhl U, Schultheiss HP (2000) The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol 35: 1778–1784CrossRefGoogle Scholar
  82. Drucker NA, Colan SD, Lewis AB et al. (1998) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89: 252–257CrossRefGoogle Scholar
  83. Kandolf R (1998) Enteroviral myocarditis and dilated cardiomyopathy. Med Klin 93: 215–222CrossRefGoogle Scholar
  84. Kuhl U, Pauschinger M, Schultheiß HP (1997) Atiopathogenetiache Differenzierung der entzündlichen Kardiomyopathie. Internist 38: 590–601PubMedCrossRefGoogle Scholar
  85. Kuhl U, Pauschinger M, Schultheiß HP (1997) Neue Konzepte zur Diagnostik der entzündlichen Herzmuskelerkrankung. Dtsch Med Wochenschr 122: 690–698PubMedCrossRefGoogle Scholar
  86. Kuhl U, Pauschinger M, Schwimmbeck PL, Lober C, Schultheiß HP (2000) Interferon-beta-Therapie bei Patienten mit enteroviraler Herzmuskelerkrankung. Z Kardiol 89: 180Google Scholar
  87. Kuhl U, Strauer BE, Schultheiss HP (1994) Methylprednisolone in chronic myocarditis. Postgrad Med J 70: S35 - S42Google Scholar
  88. Maisch B, Schonian U, Hengstenberg C et al. (1994) Immunosuppressive treatment in autoreactive myocarditis - results from a controlled trial. Postgrad Med J 70 (Suppl 1): S29 - S34PubMedGoogle Scholar
  89. Matsumori A, Matoba Y, Sasayama S (1995) Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92: 2519–2525PubMedCrossRefGoogle Scholar
  90. McNamara DM, Rosenblum WD, Janosko KM et al. (1997) Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95: 2476–2478PubMedCrossRefGoogle Scholar
  91. Miric M, Vasiljevic J, Bojic M, Popovic Z, Keserovic N, Pesic M (1996) Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 75: 596–601PubMedCrossRefGoogle Scholar
  92. Mueller J, Wallukat G, Dandel M et al. (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101: 385–391CrossRefGoogle Scholar
  93. Noutsias M, Seeberg B, Schultheiss HP, Kuhl U (1999) Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 99: 2124–2131PubMedCrossRefGoogle Scholar
  94. Pauschinger M, Bowles NE, Fuentes-Garcia FJ et al. (1999) Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99: 1348–1354PubMedCrossRefGoogle Scholar
  95. Pauschinger M, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, Kandolf R, Schultheiss HP (1999) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99: 889–895PubMedCrossRefGoogle Scholar
  96. Schultheiss HP, Pauschinger M, Dörner A, Kühl U, Bilger J, Schwimmbeck PL (1998) Entzündliche Herzmuskelerkran-Google Scholar
  97. kungen. In: Ganten D, Ruckpaul K (Hrsg) Handbuch der molekularen Medizin. Springer, Berlin Heidelberg New York Tokyo, S 111–146Google Scholar
  98. Schultheiss HP, Pauschinger M, Kühl U (1998) Pathogenese der entzündlichen Kardiomyopathie. Med Klin 93: 229–235CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Helmut Drexler
  • Karl-Heinz Kuck
  • Sabine Ernst
  • Hans-Peter Hermann
  • Gerd Hasenfuss
  • Dieter Horstkotte
  • Cornelia Piper
  • Juliane Wagener
  • Bodo-Eckhard Strauer
  • Heinz-Peter Schultheiss
  • Uwe Kühl
  • Michael Brehm
  • Dirk Hausmann
  • Franz-Josef Neumann
  • Albert Schömig
  • Christian Hamm
  • Danilo Fliser
  • Jan Menne
  • Jörg Radermacher
  • Hermann Haller
  • Christoph A. Nienaber
  • Curt Diehm
  • Gerd Hausdorf
  • Dirk Hausmann
  • Bodo Eckhard Strauer
  • Andreas Schwalen
  • Heinz-Peter Schultheiss
  • Uwe Kühl

There are no affiliations available

Personalised recommendations